Quent Capital
RARE icon

Quent Capital’s Ultragenyx Pharmaceutical RARE Stock Holding History

Quent Capital’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$957 Sell
62
-105
-63% -$2.52K ﹤0.01% 1587
2026
Q2 		$5.58K Buy
167
+123
+280% +$3.06K ﹤0.01% 1340
2026
Q1 		$922 Sell
44
-112
-72% -$2.52K ﹤0.01% 1445
2025
Q4 		$3.59K Sell
156
-60
-28% -$1.97K ﹤0.01% 1320
2025
Q3 		$6.5K Buy
+216
New +$6.48K ﹤0.01% 1098
2025
Q2 		– Sell
-183
Closed -$6.63K – 1018
2025
Q1 		$6.63K Sell
183
-14
-7% -$582 ﹤0.01% 969
2024
Q4 		$8.29K Sell
197
-29
-13% -$1.44K ﹤0.01% 964
2024
Q3 		$12.6K Hold
226
– – ﹤0.01% 974
2024
Q2 		$9.29K Buy
226
+14
+7% +$598 ﹤0.01% 1001
2024
Q1 		$9.9K Buy
212
+77
+57% +$3.63K ﹤0.01% 1021
2023
Q4 		$6.46K Sell
135
-54
-29% -$2.09K ﹤0.01% 1035
2023
Q3 		$6.74K Sell
189
-47
-20% -$1.86K ﹤0.01% 1003
2023
Q2 		$10.9K Hold
236
– – ﹤0.01% 919
2023
Q1 		$9.46K Hold
236
– – ﹤0.01% 930
2022
Q4 		$10.9K Buy
+236
New +$9.28K ﹤0.01% 880

Other funds holding RARE

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Jefferies Financial Group
Jefferies Financial Group New York $13.5B AUM 36.68% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $114B AUM 33.83% 1-Year Est. Return
Citigroup
Citigroup New York $308B AUM 40.94% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $420B AUM 34.97% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $106B AUM 32.76% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $500B AUM 36.84% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
Privium Fund Management
Privium Fund Management Amsterdam, Netherlands $516M AUM 18.66% 1-Year Est. Return

Quent Capital's RARE Position: Q3 2026 in Review

Quent Capital reduced its Ultragenyx Pharmaceutical (RARE) stake by 63% in Q3 2026, selling an estimated $2.52K and leaving 62 shares worth $957. The position accounts for ﹤0.01% of the portfolio, ranked #1587.

Quent Capital first reported a position in RARE in Q4 2022 and has held it in 15 quarters since. The position peaked at $12.6K in Q3 2024. 96 funds tracked by Wall St. Rank hold RARE as of Q3 2026.

  • Quent Capital held 62 shares of Ultragenyx Pharmaceutical worth $957 as of Q3 2026.
  • Quent Capital sold 105 Ultragenyx Pharmaceutical shares in Q3 2026, an estimated $2.52K.
  • Ultragenyx Pharmaceutical made up ﹤0.01% of Quent Capital's portfolio in Q3 2026, its #1587 holding.
  • Quent Capital first reported a position in Ultragenyx Pharmaceutical in Q4 2022 and has held it in 15 quarters since.
  • Quent Capital's Ultragenyx Pharmaceutical position peaked at $12.6K in Q3 2024.
  • 96 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q3 2026.

Based on Quent Capital's 13F filing for Q3 2026, filed 9 Nov 2026.